#United States #Los Angeles #Securities Fraud #Shareholder Rights #Unicycive Therapeutics

Unicycive Therapeutics Shareholders Sought to Lead Fraud Lawsuit

In an unfolding legal matter, Glancy Prongay Wolke & Rotter LLP has announced that shareholders of Unicycive Therapeutics, Inc. who have faced financial losses now have the opportunity to lead a class action lawsuit against the company for alleged securities fraud. Investors who believe they have been misled by the company’s statements during the specified class period—from December 29, 2025, to June 29, 2026—should be aware of this significant legal development.

Background of the Lawsuit

The class action was prompted by serious claims against Unicycive Therapeutics, particularly regarding the company's transparency about its manufacturing processes and regulatory compliance. The complaint asserts that during the defined period, the defendants failed to make accurate disclosures concerning critical aspects of the company's operations. Specifically, it is alleged that Unicycive did not properly audit its third-party manufacturing vendor, thereby lacking reasonable certainty that the vendor had addressed issues highlighted by the FDA.

Moreover, the plaintiffs point out that the company did not inform investors of a looming risk that the FDA might demand further details about the vendor's adherence to production guidelines. This negligence allegedly led to misleading statements regarding the company's prospects and operations, suggesting that approval for their product, OLC (name of the product), could be delayed. Consequently, these undisclosed risks negatively impacted investors' financial positions.

Next Steps for Affected Investors

For shareholders who suffered losses during the identified period and are interested in taking action, it is crucial to act quickly. The lead plaintiff motion must be filed in court no later than November 2, 2026. Investors wishing to assert their rights and potentially lead the case should contact the legal team at Glancy Prongay Wolke & Rotter LLP. They can offer guidance on the legal process and help investors understand their options.

Those who bought Unicycive's securities during the class period are encouraged to consider their involvement carefully. Each investor may choose to remain a passive plaintiff, but those who would like to lead the charge against the perceived wrongdoing are urged to communicate their intentions promptly. It is noteworthy that, as of now, a formal class has not yet been certified, meaning the litigation process is still very much in its initial stages.

Why Choose Glancy Prongay Wolke & Rotter LLP?

Glancy Prongay Wolke & Rotter LLP is renowned for its expertise in shareholder rights and securities litigation. With a storied history of fighting for the rights of investors, the firm has established itself as a leader in the field, earning accolades such as being named one of Law360's Securities Groups of the Year. Its reputation is bolstered by several successful outcomes in previous cases, including a ranking by Institutional Shareholder Services Securities Class Action Services for total investor recoveries.

Investors may take comfort in knowing that this high-caliber firm is ready and willing to pursue justice on their behalf. Past successful litigations have been widely reported in prominent news outlets, indicating the firm’s capability and determination to achieve favorable results for their clients.

For those affected by the potential shortcomings of Unicycive Therapeutics, this lawsuit represents not only a chance for recompense but also an opportunity to hold the company accountable for its failures in corporate governance.

For more information, investors are encouraged to reach out via email or telephone to align their interests with the ongoing legal proceedings.

Contact Information

• - Glancy Prongay Wolke & Rotter LLP

1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Email: [email protected]
Phone: 310-201-9150 | Toll-Free: 888-773-9224
Visit: Glancy Law

In summary, shareholders of Unicycive Therapeutics now face a pivotal moment to reclaim their investments within a judicial framework, harnessing their collective strength through this class action lawsuit.